91. |
92. Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapyMartina Vrankar, Izidor Kern, Karmen Stanič, 2020, original scientific article Abstract: Background: Expression of PD-L1 is the most investigated predictor of benefit from immune checkpoint blockade in advanced NSCLC but little is known about the association of PD-L1 expression and clinicopathological parameters of patients with unresectable stage III NSCLC. Methods: National registry data was searched for medical records of consecutive inoperable stage III NSCLC patients treated with ChT and RT from January 2012 to December 2017. Totally 249 patients were identified that met inclusion criteria and of those 117 patients had sufficient tissue for PD-L1 immunohistochemical staining. Results: Eighty patients (68.4%) expressed PD-L1 of >- 1% and 29.9% of more than 50%. Median PFS was 15.9 months in PD-L1 negative patients and 16.1 months in patients with PD-L1 expression >- 1% (p = 0.696). Median OS in PD-L1 negative patients was 29.9 months compared to 28.5 months in patients with PD-L1 expression >- (p = 0.888). There was no difference in median OS in patients with high PD-L1 expression (>- 50%) with 29.8 months compared to 29.9 months in those with low (1-49%) or no PD-L1 expression (p = 0.694). We found that patients who received a total dose of 60 Gy or more had significantly better median OS (32 months vs. 17.5 months, p < 0.001) as well as patients with PS 0 (33.2 vs. 20.3 months, p = 0.005). Conclusions: In our patients PD-L1 expression had no prognostic value regarding PFS and OS. Patients with good performance status and those who received a total radiation dose of more than 60 Gy had significantly better mOS.
Keywords: non small cell lung cancer, chemoradiotherapy, stage III
Published in DiRROS: 09.11.2020; Views: 1439; Downloads: 1030
 Full text (822,12 KB)
This document has many files! More... |
93. Dynamic contrast-enhanced MRI of malignant pleural mesothelioma : a comparative study of pharmacokinetic models and correlation with mRECIST criteriaMartina Vivoda Tomšič, Sotirios Bisdas, Viljem Kovač, Igor Serša, Katarina Šurlan Popović, 2019, original scientific article Abstract: BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare and aggressive thoracic malignancy that is difficult to cure. Dynamic contrast-enhanced (DCE) MRI is a functional imaging technique used to analyze tumor microvascular properties and to monitor therapy response. Purpose of this study was to compare two tracer kinetic models, the extended Tofts (ET) and the adiabatic approximation tissue homogeneity model (AATH) for analysis of DCE-MRI and examine the value of the DCE parameters to predict response to chemotherapy in patients with MPM. METHOD: This prospective, longitudinal, single tertiary radiology center study was conducted between October 2013 and July 2015. Patient underwent DCE-MRI studies at three time points: prior to therapy, during and after cisplatin-based chemotherapy. The images were analyzed using ET and AATH models. In short-term follow-up, the patients were classified as having disease control or progressive disease according to modified response evaluation criteria in solid tumors (mRECIST) criteria. Receiver operating characteristic curve analysis was used to examine specificity and sensitivity of DCE parameters for predicting response to therapy. Comparison tests were used to analyze whether derived parameters are interchangeable between the two models. RESULTS: Nineteen patients form the study population. The results indicate that the derived parameters are not interchangeable between the models. Significant correlation with response to therapy was found for AATH-calculated median pre-treatment efflux rate (kep) showing sensitivity of 83% and specificity of 100% (AUC 0.9). ET-calculated maximal pre-treatment kep showed 100% sensitivity and specificity for predicting treatment response during the early phase of the therapy and reached a favorable trend to significant prognostic value post-therapy. CONCLUSION: Both models show potential in predicting response to therapy in MPM. High pre-treatment kep values suggest MPM disease control post-chemotherapy.
Keywords: biomarker, magnetic resonance imaging, mesothelioma, perfusion, response evaluation criteria in solid
tumors, prognosis
Published in DiRROS: 23.09.2020; Views: 1330; Downloads: 966
Full text (3,44 MB)
This document has many files! More... |
94. Priporočila za obravnavo bolnikov s pljučnim rakomMartina Vrankar, Nina Boc, Izidor Kern, Aleš Rozman, Karmen Stanič, Tomaž Štupnik, Mojca Unk, Maja Ebert Moltara, Vesna Zadnik, Katja Adamič, Jernej Benedik, Marko Bitenc, Jasna But-Hadžić, Anton Crnjac, Eva Ćirić, Tanja Čufer, Goran Gačevski, Marta Globočnik Kukovica, Kristina Gornik-Kramberger, Maja Ivanetič Pantar, Staša Jelerčič, Veronika Kloboves-Prevodnik, Mile Kovačević, Luka Ležaič, Mateja Marc-Malovrh, Katja Mohorčič, Bogdan Vidmar, Dušanka Vidovič, Gregor Vlačić, Ana Lina Vodušek, Rok Zbačnik, Ivana Žagar, 2020, professional article Keywords: pljučni rak, priporočila
Published in DiRROS: 22.09.2020; Views: 1893; Downloads: 713
Full text (1,37 MB) |
95. Smernice & klinična pot za obravnavo bolnikov z melanomomPrimož Strojan, Uroš Ahčan, Marko Snoj, Boštjan Luzar, Jože Pižem, Boris Jančar, Martina Reberšek, Borut Žgavec, Tanja Planinšek Ručigaj, Aleksandra Dugovnik, 2010, dictionary, encyclopaedia, lexicon, manual, atlas, map Keywords: klasifikacija, smernice, preživetje
Published in DiRROS: 28.08.2020; Views: 1668; Downloads: 700
Full text (11,72 MB) |
96. Kaj je dobro vedeti o RDČDJanja Ocvirk, Zvezdana Hlebanja, Neva Volk, Martina Reberšek, Jernej Benedik, Marko Boc, Maja Ebert Moltara, Tanja Mesti, 2013, dictionary, encyclopaedia, lexicon, manual, atlas, map Published in DiRROS: 11.08.2020; Views: 1563; Downloads: 638
Full text (3,44 MB) |
97. Rak trebušne slinavke : kaj morate vedeti o bolezni?Janja Ocvirk, Martina Reberšek, Zvezdana Hlebanja, Erik Škof, Irena Oblak, Vaneja Velenik, Franc Anderluh, 2008, dictionary, encyclopaedia, lexicon, manual, atlas, map Keywords: dejavniki tveganja, simptomi, diagnostika, zdravljenje, bolečina
Published in DiRROS: 10.08.2020; Views: 1734; Downloads: 690
Full text (1,52 MB) |
98. Rak požiralnika : kaj morate vedeti o bolezni?Franc Anderluh, Irena Oblak, Vaneja Velenik, Janja Ocvirk, Zvezdana Hlebanja, Martina Reberšek, Mihael Sok, 2008, dictionary, encyclopaedia, lexicon, manual, atlas, map Keywords: dejavniki tveganja, simptomi, diagnostika
Published in DiRROS: 10.08.2020; Views: 1752; Downloads: 557
Full text (1,34 MB) |
99. Rak želodca : kaj morate vedeti o bolezni?Franc Anderluh, Andrej Marušič, Irena Oblak, Janja Ocvirk, Martina Reberšek, Erik Škof, Vaneja Velenik, 2006, dictionary, encyclopaedia, lexicon, manual, atlas, map Keywords: dejavniki tveganja, simptomi, diagnostika, zdravljenje
Published in DiRROS: 10.06.2020; Views: 1686; Downloads: 456
Full text (826,32 KB) |
100. Rak požiralnika : kaj morate vedeti o bolezniMarko Boc, Martina Reberšek, Janja Ocvirk, Jernej Benedik, Zvezdana Hlebanja, Neva Volk, Maja Ebert Moltara, Tanja Mesti, Franc Anderluh, Vaneja Velenik, Irena Oblak, Jasna But-Hadžić, Ajra Šečerov Ermenc, Nada Rotovnik-Kozjek, Matevž Srpčič, 2014, dictionary, encyclopaedia, lexicon, manual, atlas, map Keywords: dejavniki tveganja, simptomi, diagnostika, zdravljenje, paliativna oskrba, prehrana
Published in DiRROS: 04.06.2020; Views: 1781; Downloads: 510
Full text (634,73 KB) |
